Roundview Capital LLC boosted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 24.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 15,493 shares of the biopharmaceutical company’s stock after buying an additional 3,033 shares during the period. Roundview Capital LLC’s holdings in Bristol-Myers Squibb were worth $949,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Delphi Private Advisors LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth about $108,000. Massey Quick Simon & CO. LLC lifted its holdings in Bristol-Myers Squibb by 523.5% in the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 1,492 shares during the period. Horan Capital Advisors LLC. purchased a new stake in Bristol-Myers Squibb in the third quarter worth about $122,000. NuWave Investment Management LLC purchased a new stake in Bristol-Myers Squibb in the fourth quarter worth about $119,000. Finally, Atlantic Trust LLC purchased a new stake in Bristol-Myers Squibb in the second quarter worth about $111,000. Institutional investors and hedge funds own 71.55% of the company’s stock.
Several brokerages have commented on BMY. Vetr lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a report on Friday, December 22nd. BMO Capital Markets set a $51.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Wednesday, February 14th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Monday, January 29th. TheStreet lowered shares of Bristol-Myers Squibb from a “b” rating to a “c+” rating in a report on Thursday, March 8th. Finally, Credit Suisse Group set a $62.00 target price on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $66.30.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $66.60 on Friday. The firm has a market cap of $108,730.02, a P/E ratio of 112.88, a P/E/G ratio of 2.05 and a beta of 0.98. The company has a current ratio of 1.55, a quick ratio of 1.43 and a debt-to-equity ratio of 0.59. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.63 earnings per share. research analysts forecast that Bristol-Myers Squibb Co will post 3.2 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.40%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 271.19%.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/18/bristol-myers-squibb-co-bmy-shares-bought-by-roundview-capital-llc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.